Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary May 06, 2014	Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2014 Financial Results SOLANA BEACH, Calif. , May 6, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the First Quarter of 2014 on Tuesday, May 13, 2014 ,	View HTML Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2014 Financial Results 12.3 KB
Toggle Summary Apr 28, 2014	Evoke Pharma Announces That EVK-001 Phase 2b Results Will be Presented at Digestive Disease Week 2014 SOLANA BEACH, Calif. , April 28, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from the Company's Phase 2b clinical trial of EVK-001, a novel intranasal formulation	View HTML Evoke Pharma Announces That EVK-001 Phase 2b Results Will be Presented at Digestive Disease Week 2014 16.3 KB
Toggle Summary Apr 22, 2014	Evoke Pharma Initiates Phase 3 Clinical Trial of EVK-001 for Treatment of Gastroparesis First Patient Enrolled in Study of Novel Intranasal Formulation and Delivery of Metoclopramide	View HTML Evoke Pharma Initiates Phase 3 Clinical Trial of EVK-001 for Treatment of Gastroparesis 16.8 KB
Toggle Summary Mar 25, 2014	Evoke Pharma Reports Fourth Quarter and Year End 2013 Results SOLANA BEACH, Calif. , March 25, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013 .	View HTML Evoke Pharma Reports Fourth Quarter and Year End 2013 Results 28.1 KB
Toggle Summary Mar 10, 2014	Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2013 Financial Results SAN DIEGO , March 10, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Fourth Quarter of 2013 on Tuesday, March 25, 2014 , after	View HTML Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2013 Financial Results 12.4 KB
Toggle Summary Mar 04, 2014	Evoke Pharma to Present at 26th Annual ROTH Conference SAN DIEGO , March 4, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer , R.Ph., will be presenting at the 26 th Annual	View HTML Evoke Pharma to Present at 26th Annual ROTH Conference 14.6 KB
Toggle Summary Jan 22, 2014	Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics SAN DIEGO , Jan. 22, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing	View HTML Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics 16 KB
Toggle Summary Jan 07, 2014	Evoke Pharma to Present at Biotech Showcase(TM) 2014 SAN DIEGO , Jan. 7, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer is scheduled to present at Biotech Showcase™	View HTML Evoke Pharma to Present at Biotech Showcase(TM) 2014 15 KB
Toggle Summary Dec 02, 2013	Evoke Pharma Strengthens Executive Team With Appointments of Chief Medical Officer and Senior Director of Clinical Operations Experienced Clinical Executives to Drive Phase 3 Trial of EVK-001 for Gastroparesis	View HTML Evoke Pharma Strengthens Executive Team With Appointments of Chief Medical Officer and Senior Director of Clinical Operations 18.3 KB
Toggle Summary Nov 26, 2013	Evoke Pharma Selects SynteractHCR as Contract Research Organization for Phase 3 Trial of EVK-001 for Gastroparesis SAN DIEGO , Nov. 26, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the selection of SynteractHCR, Inc. to serve as its primary contract research organization ("CRO") for its	View HTML Evoke Pharma Selects SynteractHCR as Contract Research Organization for Phase 3 Trial of EVK-001 for Gastroparesis 17.1 KB